Market closed
ArriVent BioPharma/$AVBP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
$AVBP
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
40
Website
AVBP Metrics
BasicAdvanced
$900M
Market cap
-
P/E ratio
-$3.42
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$900M
52-week high
$34.51
52-week low
$14.35
Average daily volume
156K
Financial strength
Current ratio
19.285
Quick ratio
18.688
Long term debt to equity
0.02
Total debt to equity
0.077
Management effectiveness
Return on assets (TTM)
-24.68%
Return on equity (TTM)
-36.07%
Valuation
Price to book
3.24
Price to tangible book (TTM)
3.24
Price to free cash flow (TTM)
-9.189
Growth
Earnings per share change (TTM)
-89.61%
What the Analysts think about AVBP
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
AVBP Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AVBP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AVBP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $900M as of December 15, 2024.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of December 15, 2024.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.